TBPH
Theravance Biopharma Inc

1,001
Mkt Cap
$719.16M
Volume
220,285.00
52W High
$15.15
52W Low
$7.90
PE Ratio
61.05
TBPH Fundamentals
Price
$14.28
Prev Close
$14.14
Open
$14.25
50D MA
$14.01
Beta
0.55
Avg. Volume
453,468.38
EPS (Annual)
-$1.16
P/B
3.20
Rev/Employee
$663,721.65
Loading...
Loading...
News
all
press releases
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025
Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025 PR Newswire DUBLIN...
PR Newswire·2h ago
News Placeholder
More News
News Placeholder
Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy
Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of Power in the Periphery, a new disease education campaign for healthcare professionals (HCPs) to raise awareness and deepen...
Business Wire·11d ago
News Placeholder
Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting
Theravance Biopharma to Present New Analyses Highlighting YUPELRI (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting Theravance Biopharma to Present New Analyses Highlighting YUPELRI...
PR Newswire·13d ago
News Placeholder
Theravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·2mo ago
News Placeholder
Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
TBPH posts better-than-expected second-quarter 2025 results, boosted by Yupelri sales and licensing gains.
Zacks·2mo ago
News Placeholder
Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +42.86% and +53.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +100.00% and +33.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
Zacks·3mo ago
News Placeholder
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Zacks·3mo ago
News Placeholder
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Zacks·5mo ago

Latest TBPH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.